Healthcare -
Biotechnology - NASDAQ - US
$ 0.34
-2.16 %
$ 8.19 M
Market Cap
-0.07
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Moleculin Biotech, Inc.
| Current Assets | 5.19 M |
| Cash & Short-Term Investments | 4.28 M |
| Receivables | 20 K |
| Other Current Assets | 896 K |
| Non-Current Assets | 11.7 M |
| Long-Term Investments | 0 |
| PP&E | 424 K |
| Other Non-Current Assets | 11.3 M |
| Current Liabilities | 5.36 M |
| Accounts Payable | 2.03 M |
| Short-Term Debt | 120 K |
| Other Current Liabilities | 3.21 M |
| Non-Current Liabilities | 5.59 M |
| Long-Term Debt | 358 K |
| Other Non-Current Liabilities | 5.23 M |
EFFICIENCY
Earnings Waterfall
Moleculin Biotech, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 26.6 M |
| Operating Income | -26.6 M |
| Other Expenses | -4.88 M |
| Net Income | -21.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Moleculin Biotech, Inc.
| Net Income | -21.8 M |
| Depreciation & Amortization | 126 K |
| Capital Expenditures | -13 K |
| Stock-Based Compensation | 1.73 M |
| Change in Working Capital | 231 K |
| Others | -3.48 M |
| Free Cash Flow | -23.9 M |
Wall Street Analysts Price Targets
Moleculin Biotech, Inc.
MBRX has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
MBRX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Moleculin Biotech, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
1.4 M USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Moleculin Announces $5.9 Million Public Offering
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the pricing of a public offering consisting of 16,080,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying Series E warrants of $0.37. The Series E warrants will have an exercise price of $0.37 per share, are exercisable upon stockholder approval, and will expire five years following the initial exercise date.
globenewswire.com
- 4 weeks ago
Moleculin Participates in Virtual Investor “What This Means” Segment
Watch the “What This Means" segment here
globenewswire.com
- 1 month ago
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pediatric clinical study Enrollment and dosing are ongoing in pivotal, adaptive design Phase 3 MIRACLE trial of Annamycin in adult patients with R/R AML; Initial data readout is on track for the second half of 2025 HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has received a written response from the Office of Oncologic Diseases - Pediatric Oncology, of the U.S. Food and Drug Administration (FDA) regarding the Company's Initial Pediatric Study Plan (iPSP), which was submitted after a June 2024 end-of-phase 1/2 meeting. The FDA has agreed to a single pediatric approval study in which Annamycin (also known as naxtarubicin) in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C is referred to as “AnnAraC”) will be evaluated as second line therapy in pediatric patients with relapsed/refractory acute myeloid leukemia (R/R AML), a form of cancer.
globenewswire.com
- 1 month ago
Moleculin Participates in Virtual Investor “What This Means” Segment
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
globenewswire.com
- 1 month ago
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the release of its Soft Tissue Sarcoma (STS) Lung Mets KOL Webcast discussing the final data from its U.S. Phase 1B/2 clinical trial evaluating Annamycin as monotherapy for the treatment of soft tissue sarcoma lung metastases (MB-107). For the event, Walter Klemp, Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of Moleculin are joined by Key Opinion Leaders: Mohamad Cherry, MD, Medical Director of Hematology at Atlantic Health System; Prof.
globenewswire.com
- 1 month ago
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Annamycin delivering better performance 7 th line than would be expected even in 2 nd line for monotherapy
globenewswire.com
- 1 month ago
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Walter Klemp - Founder, President, CEO and Chairman Paul Waymack - Senior Chief Medical Officer Jonathan Foster - Executive VP & Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Jason McCarthy - Maxim Group Operator Good morning. Welcome to the Moleculin Biotech First Quarter 2025 Update Conference Call and Webcast.
seekingalpha.com
- 2 months ago
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML
globenewswire.com
- 2 months ago
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested
globenewswire.com
- 2 months ago
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET.
globenewswire.com
- 2 months ago
Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin
Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin for the treatment of acute myeloid leukemia (AML); Interim data readout expected in the second half of 2025 HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization approved “naxtarubicin1” for the non-proprietary name of the Company's next-generation anthracycline in development, Annamycin. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases and the Company believes it may have the potential to treat additional indications.
globenewswire.com
- 2 months ago
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
Company continues to expand global IP coverage and claims to major markets, now extending to June 2040 HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the U.S. Patent and Trademark Office (USPTO) has granted two additional U.S. patents with claims covering Annamycin. U.S. patent number 12,257,261 titled, “Preparation of Preliposomal Annamycin Lyophilizate”, has claims covering methods of making liposomal Annamycin and U.S. patent 12,257,262 titled “Method of Reconstituting Liposomal Annamycin“, has claims covering methods of making liposomal Annamycin suspension.
globenewswire.com
- 2 months ago
8. Profile
Summary
Moleculin Biotech, Inc. MBRX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 8.19 M
Dividend Yield
0.00%
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Contact
5300 Memorial Drive, Houston, TX, 77007
https://www.moleculin.com
IPO
Date
June 2, 2016
Employees
17
Officers
Mr. Walter V. Klemp
Co-Founder, Chairman, President & Chief Executive Officer
Dr. Waldemar Priebe Ph.D.
Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
Dr. Donald H. Picker Ph.D.
Chief Scientific Officer
Dr. John Paul Waymack M.D., Sc.D.
Senior Chief Medical Officer
Mr. Jonathan P. Foster CPA
Executive Vice President & Chief Financial Officer